172 related articles for article (PubMed ID: 24099397)
1. Nanoformulations for delivery of biomolecules: focus on liposomal variants for siRNA delivery.
Dash TK; Konkimalla VB
Crit Rev Ther Drug Carrier Syst; 2013; 30(6):469-93. PubMed ID: 24099397
[TBL] [Abstract][Full Text] [Related]
2. Liposomal systems as viable drug delivery technology for skin cancer sites with an outlook on lipid-based delivery vehicles and diagnostic imaging inputs for skin conditions'.
Akhtar N; Khan RA
Prog Lipid Res; 2016 Oct; 64():192-230. PubMed ID: 27697511
[TBL] [Abstract][Full Text] [Related]
3. Research progress on siRNA delivery with nonviral carriers.
Gao Y; Liu XL; Li XR
Int J Nanomedicine; 2011; 6():1017-25. PubMed ID: 21720513
[TBL] [Abstract][Full Text] [Related]
4. Translational siRNA therapeutics using liposomal carriers: prospects & challenges.
Bhavsar D; Subramanian K; Sethuraman S; Krishnan UM
Curr Gene Ther; 2012 Aug; 12(4):315-32. PubMed ID: 22856607
[TBL] [Abstract][Full Text] [Related]
5. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design.
Buyens K; De Smedt SC; Braeckmans K; Demeester J; Peeters L; van Grunsven LA; de Mollerat du Jeu X; Sawant R; Torchilin V; Farkasova K; Ogris M; Sanders NN
J Control Release; 2012 Mar; 158(3):362-70. PubMed ID: 22023849
[TBL] [Abstract][Full Text] [Related]
6. siRNA-Conjugated Nanoparticles to Treat Ovarian Cancer.
Halbur C; Choudhury N; Chen M; Kim JH; Chung EJ
SLAS Technol; 2019 Apr; 24(2):137-150. PubMed ID: 30616494
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals.
Sarmento B
Ther Deliv; 2010 Aug; 1(2):231-5. PubMed ID: 22816130
[TBL] [Abstract][Full Text] [Related]
8. Challenges in development of targeted liposomal therapeutics.
Sawant RR; Torchilin VP
AAPS J; 2012 Jun; 14(2):303-15. PubMed ID: 22415612
[TBL] [Abstract][Full Text] [Related]
9. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy.
Lee J; Ahn HJ
Biochem Biophys Res Commun; 2018 Sep; 503(3):1716-1722. PubMed ID: 30049442
[TBL] [Abstract][Full Text] [Related]
10. Engineering RNA for targeted siRNA delivery and medical application.
Guo P; Coban O; Snead NM; Trebley J; Hoeprich S; Guo S; Shu Y
Adv Drug Deliv Rev; 2010 Apr; 62(6):650-66. PubMed ID: 20230868
[TBL] [Abstract][Full Text] [Related]
11. Solid Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceuticals: A Review of Opportunities, Challenges, and Delivery Applications.
Alwani S; Wasan EK; Badea I
Mol Pharm; 2024 Jul; 21(7):3084-3102. PubMed ID: 38828798
[TBL] [Abstract][Full Text] [Related]
12. Strategies for in vivo delivery of siRNAs: recent progress.
Higuchi Y; Kawakami S; Hashida M
BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive mathematical model of drug release kinetics from nano-liposomes, derived from optimization studies of cationic PEGylated liposomal doxorubicin formulations for drug-gene delivery.
Haghiralsadat F; Amoabediny G; Helder MN; Naderinezhad S; Sheikhha MH; Forouzanfar T; Zandieh-Doulabi B
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):169-177. PubMed ID: 28376641
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in liposomal drug-delivery systems.
Chonn A; Cullis PR
Curr Opin Biotechnol; 1995 Dec; 6(6):698-708. PubMed ID: 8527843
[TBL] [Abstract][Full Text] [Related]
15. Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.
Garbuzenko OB; Saad M; Betigeri S; Zhang M; Vetcher AA; Soldatenkov VA; Reimer DC; Pozharov VP; Minko T
Pharm Res; 2009 Feb; 26(2):382-94. PubMed ID: 18958402
[TBL] [Abstract][Full Text] [Related]
16. The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers.
Joo MK; Yhee JY; Kim SH; Kim K
J Control Release; 2014 Nov; 193():113-21. PubMed ID: 24862319
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional pH-Sensitive Amino Lipids for siRNA Delivery.
Gujrati M; Vaidya A; Lu ZR
Bioconjug Chem; 2016 Jan; 27(1):19-35. PubMed ID: 26629982
[TBL] [Abstract][Full Text] [Related]
18. Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders.
Maheshwari R; Tekade M; Sharma PA; Tekade RK
Curr Pharm Des; 2015; 21(30):4427-40. PubMed ID: 26471319
[TBL] [Abstract][Full Text] [Related]
19. Biomaterials in siRNA Delivery: A Comprehensive Review.
Ho W; Zhang XQ; Xu X
Adv Healthc Mater; 2016 Nov; 5(21):2715-2731. PubMed ID: 27700013
[TBL] [Abstract][Full Text] [Related]
20. Multifunctional nanocarrier based on clay nanotubes for efficient intracellular siRNA delivery and gene silencing.
Wu H; Shi Y; Huang C; Zhang Y; Wu J; Shen H; Jia N
J Biomater Appl; 2014 Apr; 28(8):1180-9. PubMed ID: 23985535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
